Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
IFNA14 Biologics Sequence Review Report 2026: Interferon alpha-14 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CFH Biologics Sequence Review Report 2026: Complement factor H Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CFH protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FZD9 Biologics Sequence Review Report 2026: Frizzled-9 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FZD9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FZD6 Biologics Sequence Review Report 2026: Frizzled-6 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FZD6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
C4B Biologics Sequence Review Report 2026: Complement C4-B Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of C4B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
C4A Biologics Sequence Review Report 2026: Complement C4-A Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of C4A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
C5 Biologics Sequence Review Report 2026: Complement C5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of C5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TRPM2 Biologics Sequence Review Report 2026: Transient receptor potential cation channel subfamily M member 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRPM2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
C3 Biologics Sequence Review Report 2026: Complement C3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of C3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PLXNB1 Biologics Sequence Review Report 2026: Plexin-B1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PLXNB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NCAM1 Biologics Sequence Review Report 2026: Neural cell adhesion molecule 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NCAM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MRC1 Biologics Sequence Review Report 2026: Macrophage mannose receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MRC1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.